{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:29:33Z","timestamp":1793896173851,"version":"4.8.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Severe eosinophilic asthma (SEA) in the presence of chronic rhinosinusitis with nasal polyps (CRSwNP) indicates the presence of a more extensive eosinophilic inflammation. <jats:italic>Post-hoc<\/jats:italic> analyses from a pivotal clinical trial have demonstrated the enhanced efficacy of benralizumab on asthma outcomes in patients with CRSwNP as a comorbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a <jats:italic>post-hoc<\/jats:italic> analysis from the Italian multi-center observational retrospective ANANKE study. Patients were divided into two groups based on self-reported CRSwNP. Baseline clinical and laboratory features in the 12 months prior to benralizumab prescription were collected. Data of change over time of blood eosinophils, annualized exacerbations rates (AER), asthma control, lung function, oral corticosteroids (OCS) use, and benralizumab discontinuation were collected during the observation period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline, the 110 patients with CRSwNP were less frequently female (50.9% vs 74.2%) and obese (9.1% vs. 22.6%) with higher eosinophils (605 vs. 500 cells\/mm<jats:sup>3<\/jats:sup>) and OCS use when compared to patients without CRSwNP. Similar reductions of AER were seen (-95.8% vs. \u221291.5% for any exacerbation and \u221299.1% vs. \u221292.2% for severe exacerbations in patients with and without CRSwNP, respectively). During benralizumab treatment, comorbid SEA+CRSwNP was associated with a lower risk of any exacerbation (<jats:italic>p<\/jats:italic> = 0.0017) and severe exacerbations (<jats:italic>p<\/jats:italic> = 0.025). After a mean \u00b1 SD exposure of 10.3 \u00b1 5.0 months, half of the SEA+CRSwNP patients eliminated OCS use. No discontinuation for safety reasons was recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study helped to confirm the baseline clinical features that distinguish patients with and without CRSwNP being prescribed benralizumab. Numerically enhanced OCS reduction and lower exacerbation risk were observed in patients with SEA and comorbid CRSwNP treated with benralizumab.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2022.881218","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:21:05Z","timestamp":1652851265000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis"],"prefix":"10.3389","volume":"3","author":[{"given":"Maria","family":"D'Amato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bracciale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brussino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Caiaffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"De Michele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elide Anna","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Schino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Boarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Giacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"Biomed Res Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.suppl_2.S26","article-title":"United airways disease: therapeutic aspects","author":"Passalacqua","year":"2000","journal-title":"Thorax."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.pupt.2020.101966","article-title":"Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma","volume":"64","author":"Menzella","year":"2020","journal-title":"Pulm Pharmacol Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test?A survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","article-title":"Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis","volume":"36","author":"Chen","year":"2020","journal-title":"Curr Med Res Opin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/alr.21258","article-title":"The association between allergy and chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations","volume":"4","author":"Wilson","year":"2014","journal-title":"Int Forum Allergy Rhinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e047230","DOI":"10.1136\/bmjopen-2020-047230","article-title":"Association between obesity and chronic rhinosinusitis with nasal polyps: a national population-based study","volume":"11","author":"Nam","year":"2021","journal-title":"BMJ Open."},{"key":"B19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1164\/rccm.201412-2278OC","article-title":"Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease","volume":"192","author":"Stevens","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","article-title":"Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis","volume":"20","author":"Prazma","year":"2019","journal-title":"Respir Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MCP.0000000000000640","article-title":"The impact of comorbidities on severe asthma","volume":"26","author":"Rogliani","year":"2020","journal-title":"Curr Opin Pulm Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1183\/09031936.00121308","article-title":"Influence of comorbid conditions on asthma","volume":"33","author":"Boulet","year":"2009","journal-title":"Eur Respir J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","article-title":"Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A Delphi study","volume":"203","author":"Suehs","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/02770903.2019.1705333","article-title":"Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma","volume":"58","author":"Bourdin","year":"2021","journal-title":"J Asthma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy."},{"key":"B31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-World effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2222.2005.02194.x","article-title":"Airway inflammation in nasal polyposis: immunopathological aspects of relation to asthma","volume":"35","author":"Ediger","year":"2005","journal-title":"Clin Exp Allergy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"631660","DOI":"10.3389\/fphar.2021.631660","article-title":"Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: our real-life experience","volume":"12","author":"Scioscia","year":"2021","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"A1205","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1205","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"203","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract."}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.881218\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:21:07Z","timestamp":1652851267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2022.881218\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":34,"alternative-id":["10.3389\/falgy.2022.881218"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2022.881218","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"881218"}}